Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Mark A. Sussman is active.

Publication


Featured researches published by Mark A. Sussman.


Circulation | 2000

Decreased SLIM1 Expression and Increased Gelsolin Expression in Failing Human Hearts Measured by High-Density Oligonucleotide Arrays

Jiacheng Yang; Christine S. Moravec; Mark A. Sussman; Nicholas R. DiPaola; Dechen Fu; Lesley Hawthorn; Christina A. Mitchell; James B. Young; Gary S. Francis; Patrick M. McCarthy; Meredith Bond

Background—Failing human hearts are characterized by altered cytoskeletal and myofibrillar organization, impaired signal transduction, abnormal protein turnover, and impaired energy metabolism. Thus, expression of multiple classes of genes is likely to be altered in human heart failure. Methods and Results—We used high-density oligonucleotide arrays to explore changes in expression of ≈7000 genes in 2 nonfailing and 2 failing human hearts with diagnoses of end-stage ischemic and dilated cardiomyopathy, respectively. We report altered expression of (1) cytoskeletal and myofibrillar genes (striated muscle LIM protein-1 [SLIM1], myomesin, nonsarcomeric myosin regulatory light chain-2 [MLC2], and &bgr;-actin); (2) genes responsible for degradation and disassembly of myocardial proteins (&agr;1-antichymotrypsin, ubiquitin, and gelsolin); (3) genes involved in metabolism (ATP synthase &agr;-subunit, succinate dehydrogenase flavoprotein [SDH Fp] subunit, aldose reductase, and TIM17 preprotein translocase); (4) genes responsible for protein synthesis (elongation factor-2 [EF-2], eukaryotic initiation factor-4AII, and transcription factor homologue-HBZ17); and (5) genes encoding stress proteins (&agr;B-crystallin and &mgr;-crystallin). In 5 additional failing hearts and 4 additional nonfailing controls, we then compared expression of proteins encoded by the differentially expressed genes, &agr;B-crystallin, SLIM1, gelsolin, &agr;1-antichymotrypsin, and ubiquitin. In each case, changes in protein expression were consistent with changes in transcript measured by microarray analysis. Gelsolin protein expression was also increased in cardiomyopathic hearts from tropomodulin-overexpressing (TOT) mice and rac1-expressing (racET) mice. Conclusions—Altered expression of the genes identified in this study may contribute to development of the heart failure phenotype and/or represent compensatory mechanisms to sustain cardiac function in failing human hearts.


Journal of Clinical Investigation | 2000

Altered focal adhesion regulation correlates with cardiomyopathy in mice expressing constitutively active rac1

Mark A. Sussman; Sara Welch; Angela Walker; Raisa Klevitsky; Timothy E. Hewett; Robert L. Price; Erik Schaefer; Karen Yager

The ras family of small GTP-binding proteins exerts powerful effects upon cell structure and function. One member of this family, rac, induces actin cytoskeletal reorganization in nonmuscle cells and hypertrophic changes in cultured cardiomyocytes. To examine the effect of rac1 activation upon cardiac structure and function, transgenic mice were created that express constitutively activated rac1 specifically in the myocardium. Transgenic rac1 protein was expressed at levels comparable to endogenous rac levels, with activation of the rac1 signaling pathway resulting in two distinct cardiomyopathic phenotypes: a lethal dilated phenotype associated with neonatal activation of the transgene and a transient cardiac hypertrophy seen among juvenile mice that resolved with age. Neither phenotype showed myofibril disarray and hypertrophic hearts were hypercontractilein working heart analyses. The rac1 target p21-activated kinase translocated from a cytosolic to a cytoskeletal distribution, suggesting that rac1 activation was inducing focal adhesion reorganization. Corroborating results showed altered localizations of src in dilated cardiomyopathy and paxillin in both cardiomyopathic phenotypes. This study, the first examination of rac1-mediated cardiac effects in vivo, demonstrates that dilation and hypertrophy can share a common molecular origin and presents evidence that both timing and concurrent signaling from multiple pathways can influence cardiac remodeling.


Journal of Clinical Investigation | 1998

Myofibril degeneration caused by tropomodulin overexpression leads to dilated cardiomyopathy in juvenile mice.

Mark A. Sussman; Sara Welch; Natalie Cambon; Raisa Klevitsky; Timothy E. Hewett; Robert L. Price; Sandra A. Witt; Thomas R. Kimball

Loss of myofibril organization is a common feature of chronic dilated and progressive cardiomyopathy. To study how the heart compensates for myofibril degeneration, transgenic mice were created that undergo progressive loss of myofibrils after birth. Myofibril degeneration was induced by overexpression of tropomodulin, a component of the thin filament complex which determines and maintains sarcomeric actin filament length. The tropomodulin cDNA was placed under control of the alpha-myosin heavy chain gene promoter to overexpress tropomodulin specifically in the myocardium. Offspring with the most severe phenotype showed cardiomyopathic changes between 2 and 4 wk after birth. Hearts from these mice present characteristics consistent with dilated cardiomyopathy and a failed hypertrophic response. Histological analysis showed widespread loss of myofibril organization. Confocal microscopy of isolated cardiomyocytes revealed intense tropomodulin immunoreactivity in transgenic mice together with abnormal coincidence of tropomodulin and alpha-actinin reactivity at Z discs. Contractile function was compromised severely as determined by echocardiographic analyses and isolated Langendorff heart preparations. This novel experimentally induced cardiomyopathy will be useful for understanding dilated cardiomyopathy and the effect of thin filament-based myofibril degeneration upon cardiac structure and function.


Circulation Research | 2002

Cardiac-Specific IGF-1 Expression Attenuates Dilated Cardiomyopathy in Tropomodulin-Overexpressing Transgenic Mice

Sara Welch; David M. Plank; Sandra A. Witt; Betty J. Glascock; Erik Schaefer; Stefano Chimenti; Anna Maria Andreoli; Federica Limana; Annarosa Leri; Jan Kajstura; Piero Anversa; Mark A. Sussman

To test the hypothesis that early interventional treatment with insulin-like growth factor-1 (IGF-1) alleviates subsequent development of dilated cardiomyopathy, cardiac-specific IGF-1 expression was introduced by selective cross-breeding into a transgenic mouse model of heart failure that displays phenotypic characteristics of severe dilation. Hemodynamic, structural, and cellular parameters of the heart were compared between nontransgenic, tropomodulin-overexpressing cardiomyopathic, and the hybrid tropomodulin/IGF-1-overexpressing mice. Beneficial effects of IGF-1 were apparent by multiple indices of cardiac structure and function, including normalization of heart mass, anatomy, hemodynamics, and apoptosis. IGF-1 expression also acted as a proliferative stimulus as evidenced by calculated increases in myocyte number as well as expression of Ki67, a nuclear marker of cellular replication. Cellular analyses revealed that IGF-1 inhibited characteristic cardiomyocyte elongation in dilated hearts and restored calcium dynamics comparable to that observed in normal cells. Collectively, these results provide novel information regarding the ability of IGF-1 to inhibit progression of cardiomyopathic disease in a defined model system and suggest that heart failure may benefit from early interventional IGF-1 treatment.


Circulation Research | 1998

Altered Expression of Tropomodulin in Cardiomyocytes Disrupts the Sarcomeric Structure of Myofibrils

Mark A. Sussman; Susanna Baqué; Chang Sub Uhm; Mathew P. Daniels; Robert L. Price; David G. Simpson; Louis Terracio; Larry Kedes

Tropomodulin is a tropomyosin-binding protein that terminates pointed-end actin filament polymerization. To test the hypothesis that regulation of tropomodulin:actin filament stoichiometry is critical for maintenance of actin filament length, tropomodulin levels were altered in cells by infection with recombinant adenoviral expression vectors, which produce either sense or antisense tropomodulin mRNA. Neonatal rat cardiomyocytes were infected, and sarcomeric actin filament organization was examined. Confocal microscopy indicated that overexpression of tropomodulin protein shortened actin filaments and caused myofibril degeneration. In contrast, decreased tropomodulin content resulted in the formation of abnormally long actin filament bundles. Despite changes in myofibril structure caused by altered tropomodulin expression, total protein turnover of the cardiomyocytes was unaffected. Biochemical analyses of infected cardiomyocytes indicated that changes in actin distribution, rather than altered actin content, accounted for myofibril reorganization. Ultrastructural analysis showed thin-filament disarray and revealed the presence of leptomeres after tropomodulin overexpression. Tropomodulin-mediated effects constitute a novel mechanism to control actin filaments, and our findings demonstrate that regulated tropomodulin expression is necessary to maintain stabilized actin filament structures in cardiac muscle cells.


Science | 1998

Prevention of cardiac hypertrophy in mice by calcineurin inhibition

Mark A. Sussman; Hae W. Lim; Natalie Gude; Tyler Taigen; Eric N. Olson; Jeffrey Robbins; Melissa C. Colbert; Antonio Gualberto; David F. Wieczorek; Jeffery D. Molkentin


Journal of Cell Biology | 2001

Alterations at the Intercalated Disk Associated with the Absence of Muscle Lim Protein

Elisabeth Ehler; Robert Horowits; Christian Zuppinger; Robert L. Price; Evelyne Perriard; Martin Leu; Pico Caroni; Mark A. Sussman; Hans M. Eppenberger; Jean-Claude Perriard


American Journal of Physiology-heart and Circulatory Physiology | 2003

Calcium Dynamics in the Failing Heart: Restoration by β-Adrenergic Receptor Blockade

David M. Plank; Atsuko Yatani; Honda Ritsu; Sandra A. Witt; Betty J. Glascock; M. Jane Lalli; Muthu Periasamy; Céline Fiset; Nancy A. Benkusky; Héctor H. Valdivia; Mark A. Sussman


American Journal of Physiology-heart and Circulatory Physiology | 2005

Myocardial subproteomic analysis of a constitutively active Rac1 expressing transgenic mouse with lethal myocardial hypertrophy

Nina Buscemi; Chris Murray; Anianda Doherty-Kirby; Gilles A. Lajoie; Mark A. Sussman; Jennifer E. Van Eyk


Archive | 2014

Making it stick: chasing the optimal stem cells for cardiac

Pearl Quijada; Mark A. Sussman

Collaboration


Dive into the Mark A. Sussman's collaboration.

Top Co-Authors

Avatar

Natalie Gude

San Diego State University

View shared research outputs
Top Co-Authors

Avatar

Robert L. Price

University of South Carolina

View shared research outputs
Top Co-Authors

Avatar

Sara Welch

Cincinnati Children's Hospital Medical Center

View shared research outputs
Top Co-Authors

Avatar

Raisa Klevitsky

Cincinnati Children's Hospital Medical Center

View shared research outputs
Top Co-Authors

Avatar

Sandra A. Witt

Cincinnati Children's Hospital Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Betty J. Glascock

Cincinnati Children's Hospital Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

David M. Plank

Cincinnati Children's Hospital Medical Center

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge